PROCEPT BioRobotics (PRCT) Operating Leases (2020 - 2026)

PROCEPT BioRobotics (PRCT) has reported Operating Leases for 7 consecutive years, with $25.8 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Operating Leases fell 7.39% year-over-year to $25.8 million in Q2 2026; TTM through Jun 2026 was $25.8 million, a 7.39% decrease from a year earlier, with the FY2025 full-year figure at $24.7 million, down 8.24% from the prior year.
• Operating Leases was $25.8 million for Q2 2026 at PROCEPT BioRobotics, down from $26.3 million in the prior quarter.
• Over five years, Operating Leases peaked at $30.0 million in Q1 2024 and troughed at $3.1 million in Q2 2022.
• A 5-year average of $24.7 million and a median of $27.1 million in 2024 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases surged 1104.17% in 2022 and dropped 8.24% in 2025, its largest moves.
• Over 5 years, Operating Leases stood at $24.0 million in 2022, then gained by 9.21% to $26.2 million in 2023, then advanced by 2.62% to $26.9 million in 2024, then retreated by 8.24% to $24.7 million in 2025, then advanced by 4.59% to $25.8 million in 2026.
• The last three Operating Leases figures came in at $25.8 million (Q2 2026), $26.3 million (Q1 2026), and $24.7 million (Q4 2025), per Business Quant data.